LEXXHIGH SIGNALFINANCIAL10-K

LEXX experienced a severe cash burn with stockholders' equity declining by nearly two-thirds while revenue grew substantially.

The company consumed approximately $5 million in cash over the year despite revenue growth that was substantially higher, indicating significant operational cash burn that raises questions about runway and capital needs. The dramatic decline in total assets and equity suggests the company is burning through its capital base faster than it can generate returns from its DehydraTECH drug delivery platform.

Comparing 2025-11-28 vs 2024-11-26View on EDGAR →
FINANCIAL ANALYSIS

LEXX shows a troubling financial picture with total assets declining from $8.9M to $4.2M and stockholders' equity falling from $8.0M to $3.0M, indicating substantial cash consumption. While revenue and gross profit grew meaningfully, this growth was insufficient to offset the significant operational cash burn. The company's financial position has deteriorated markedly despite business development progress, suggesting potential funding needs in the near term.

FINANCIAL STATEMENT CHANGES
Stockholders Equity
Balance Sheet
-62.8%
$8.0M→$3.0M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Current Assets
Balance Sheet
-56.1%
$7.9M→$3.5M

Current assets declined 56.1% — monitor working capital adequacy and short-term liquidity.

Gross Profit
P&L
+53.1%
$459K→$703K

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Total Assets
Balance Sheet
-52.9%
$8.9M→$4.2M

Total assets contracted 52.9% — asset sales, write-downs, or balance sheet optimization underway.

Revenue
P&L
+52%
$464K→$706K

Strong top-line growth of 52% — accelerating demand or successful expansion into new markets.

Cash & Equivalents
Balance Sheet
-46.8%
$10.9M→$5.8M

Cash declined 46.8% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Capital Expenditure
Cash Flow
-42.7%
$43K→$25K

Capex reduced 42.7% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Current Liabilities
Balance Sheet
+35.8%
$1.1M→$1.5M

Current liabilities surged 35.8% — significant near-term obligations; verify ability to meet short-term debt.

Total Liabilities
Balance Sheet
+30.1%
$1.2M→$1.6M

Liabilities grew 30.1% — significant increase in debt or obligations, assess impact on financial flexibility.

LANGUAGE CHANGES
NEW — 2025-11-28
PRIOR — 2024-11-26
ADDED
During the three months ended August 31, 2025, no director or officer of the Company adopted or terminated a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement, as each term is defined in Item 408(a) of Regulation S-K.
is a biotechnology company dedicated to the enhancement of the bioavailability of a diverse and broad range of active pharmaceutical ingredients ( APIs ) using our patented DehydraTECH TM drug delivery technology.
DehydraTECH can be used with a wide range of active molecules including glucagon-like peptide-1 drugs ( GLP-1 ) and glucose-dependent insulinotropic polypeptide drugs ( GIP ), vitamins, pain medications, hormones, antivirals, nicotine and its analogs, and cannabinoids.
DehydraTECH can be implemented in a multitude of ingestible product formats including oral suspensions, tablets, capsules, foods, beverages, and oral pouches.
While the Company s primary focus is on pharmaceutical drug products, this technology extends across many product categories including nutraceuticals, foods and beverages.
+7 more — sign up free →
REMOVED
is a biotechnology company dedicated to the enhancement of the bioavailability of a broad range of active pharmaceutical ingredients ( APIs ) using our patented DehydraTECH TM drug delivery-enabling platform technology.
DehydraTECH can be used with a wide range of active molecules including glucagon-like peptide-1 drugs ( GLP-1 ) and glucose -dependent insulinotropic polypeptide drugs ( GIP ), vitamins, pain medications, hormones, phosphodiesterase type 5 ( PDE5 ) inhibitors, antivirals, nicotine and its analogs, and cannabinoids.
DehydraTECH can be implemented in a multitude of ingestible or topically administered product formats including oral suspensions, tablets, capsules, foods, beverages, creams, lotions, and skin patches.
While the Company s primary focus is on pharmaceutical drug products, this technology extends across many product categories including foods, beverages, cosmetics and nutraceuticals.
Our current patent portfolio includes patent family applications or grants pertaining to Lexaria s compositions, methods of use in improving API bioavailability and palatability and methods of treatment for a range of therapeutic indications, orally or topically, for a wide variety of APIs encompassing cannabinoids; fat soluble vitamins; NSAID pain medications; and nicotine and its analogs.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →